TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up

Tempest Therapeutics, Inc. (TPST) announced that it is planning to explore strategic options to advance the clinical studies on its pipeline candidates aimed at increasing stockholder value. The strategic alternatives may include potential mergers and acquisitions, partnerships, licensing arrangements, or other such transactions.Tempest is developing amezalpat (TPST-1120), a PPAR-alpha antagonist, for the first-line treatment of unresectable or metastatic hepatocellular carcinoma (HCC), the most common type ...